These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
377 related articles for article (PubMed ID: 2470557)
1. Loxiglumide. A new proglumide analog with potent cholecystokinin antagonistic activity in the rat pancreas. Otsuki M; Fujii M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S Dig Dis Sci; 1989 Jun; 34(6):857-64. PubMed ID: 2470557 [TBL] [Abstract][Full Text] [Related]
2. [Inhibitory effect of a new proglumide derivative, loxiglumide, on CCK action in isolated rat pancreatic acini]. Fujii M; Otsuki M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S Nihon Shokakibyo Gakkai Zasshi; 1989 Jan; 86(1):77-82. PubMed ID: 2471851 [TBL] [Abstract][Full Text] [Related]
3. Effects of a new proglumide analogue CR 1392 on pancreatic exocrine secretion in the rat. Otsuki M; Fujii M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S Digestion; 1989; 42(2):61-9. PubMed ID: 2475379 [TBL] [Abstract][Full Text] [Related]
4. Pharmacologic profile of TS-941, a new benzodiazepine derivative cholecystokinin-receptor antagonist, in in vitro isolated rat pancreatic acini. Tashiro M; Hirohata Y; Kihara Y; Akiyama T; Otsuki M Pancreas; 1999 Mar; 18(2):156-64. PubMed ID: 10090413 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist. Akiyama T; Tachibana I; Hirohata Y; Shirohara H; Yamamoto M; Otsuki M Br J Pharmacol; 1996 Apr; 117(7):1558-64. PubMed ID: 8730754 [TBL] [Abstract][Full Text] [Related]
6. CR-1409: a potent inhibitor of cholecystokinin-stimulated amylase release and cholecystokinin binding in rat pancreatic acini. Iwamoto Y; Yamamoto R; Kuzuya T Pancreas; 1987; 2(1):85-90. PubMed ID: 2437574 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vitro. Taniguchi H; Yazaki N; Endo T; Nagasaki M Eur J Pharmacol; 1996 May; 304(1-3):147-54. PubMed ID: 8813597 [TBL] [Abstract][Full Text] [Related]
8. Characterization of a new cholecystokinin receptor antagonist FK480 in in vitro isolated rat pancreatic acini. Akiyama T; Otsuki M Pancreas; 1994 May; 9(3):324-31. PubMed ID: 8022754 [TBL] [Abstract][Full Text] [Related]
9. [Inhibitory effect of CR 1409 (cholecystokinin antagonist) on pancreatic exocrine secretion in rats]. Shiratori K; Watanabe S; Shimizu K; Moriyoshi Y; Chang JH; Takeuchi T Nihon Shokakibyo Gakkai Zasshi; 1989 Jan; 86(1):70-6. PubMed ID: 2471850 [TBL] [Abstract][Full Text] [Related]
10. Proglumide analogues CR 1409 and CR 1392 inhibit cholecystokinin-stimulated insulin release more potently than exocrine secretion from the isolated perfused rat pancreas. Okabayashi Y; Otsuki M; Nakamura T; Fujii M; Tani S; Fujisawa T; Koide M; Hasegawa H; Baba S Pancreas; 1990 May; 5(3):291-7. PubMed ID: 2188254 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo. Taniguchi H; Yazaki N; Yomota E; Shikano T; Endo T; Nagasaki M Eur J Pharmacol; 1996 Sep; 312(2):227-33. PubMed ID: 8894600 [TBL] [Abstract][Full Text] [Related]
12. New proglumide-analogue CCK receptor antagonists: very potent and selective for peripheral tissues. Niederau C; Niederau M; Williams JA; Grendell JH Am J Physiol; 1986 Jun; 250(6 Pt 1):G856-60. PubMed ID: 2424321 [TBL] [Abstract][Full Text] [Related]
13. Effects of loxiglumide on pancreatic exocrine secretion stimulated by cholecystokinin-8 in conscious dogs. Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Kasai H; Kimura K; Fujii M Arzneimittelforschung; 1998 Jan; 48(1):52-4. PubMed ID: 9522032 [TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo effect of proglumide on cholecystokinin-stimulated amylase release in mouse pancreatic acini. Iwamoto Y; Nakamura R; Akanuma Y Gastroenterol Jpn; 1984 Feb; 19(1):53-8. PubMed ID: 6202584 [TBL] [Abstract][Full Text] [Related]
15. CCK receptor antagonist loxiglumide alters uptake of CCK in perfused liver and pancreatic acini of the rat. Beckh K; Göke R; Ruff W; Koop I; Arnold R; Adler G Digestion; 1991; 48(2):98-103. PubMed ID: 1868975 [TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of intraduodenal infusion of loxiglumide on pancreatic exocrine secretion. Tanikawa M; Hayakawa T; Kondo T; Shibata T; Kitagawa M; Kodaira T; Hamaoka T Arzneimittelforschung; 1993 Jan; 43(1):35-9. PubMed ID: 8447844 [TBL] [Abstract][Full Text] [Related]
17. Comparison of loxiglumide, a cholecystokinin receptor antagonist, and atropine on hormonal and meal-stimulated pancreatic secretion in man. Gabryelewicz A; Kulesza E; Konturek SJ Scand J Gastroenterol; 1990 Jul; 25(7):731-8. PubMed ID: 2396088 [TBL] [Abstract][Full Text] [Related]
18. Structural features of various proglumide-related cholecystokinin receptor antagonists. Jensen RT; Zhou ZC; Murphy RB; Jones SW; Setnikar I; Rovati LA; Gardner JD Am J Physiol; 1986 Dec; 251(6 Pt 1):G839-46. PubMed ID: 2431626 [TBL] [Abstract][Full Text] [Related]
19. Characterization of a new CCK antagonist, L364,718: in vitro and in vivo studies. Louie DS; Liang JP; Owyang C Am J Physiol; 1988 Sep; 255(3 Pt 1):G261-6. PubMed ID: 2458681 [TBL] [Abstract][Full Text] [Related]
20. Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man. Hildebrand P; Beglinger C; Gyr K; Jansen JB; Rovati LC; Zuercher M; Lamers CB; Setnikar I; Stalder GA J Clin Invest; 1990 Mar; 85(3):640-6. PubMed ID: 2312719 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]